GOODIX
27.2.2017 18:53:16 CET | Business Wire | Press release
Goodix (Shanghai Stock Exchange:603160), the premier developer of human interface and biometric solutions for mobile devices, announced today that Huawei P10 and P10 Plus, flagship smartphones of 2017 just launched at Mobile World Congress 2017, are using Invisible Fingerprint Sensor (IFS™) from Goodix.
Huawei’s P10 and P10 Plus smartphones have stylish, integrated screen panel design. The Home key has IFS™ embedded under the screen panel, allowing fingerprint authentication through the glass. IFS™ from Goodix enables the elegant and slim design of P10 and P10 Plus while providing secure and easy-to-use fingerprint authentication. This safeguards the smartphone and secures mobile transactions.
World’s first IFS™ solution meets Huawei’s design needs
Traditionally, a button needs to be placed on the front or at the back of a smartphone in order to install a fingerprint sensor. This means manufacturers need to open a hole on the glass panel for the button. This occupies space, affects the overall phone design and increases the complexity of manufacturing process. Goodix’s IFS™ addresses these issues by seamlessly integrating the sensor right under the glass panel without the need to drill a hole and place a button.
Goodix and Huawei share the same vision of innovating latest technologies to fulfill people’s desires and needs. The longstanding partnership between the two companies is a great success. Prior to the P10 and P10 Plus, a number of Huawei smartphones already use various Goodix’s fingerprint authentication and touchscreen controller solutions. The two companies will continue to innovate to provide safer, more convenient and intelligent technology to mobile users.
IFS™ gives manufacturers more flexibility to develop stylish, slim phone designs. It also supports thick glass panels and improves the water and dust resistance. All this combines to deliver a better user experience and higher reliability.
From R&D to successful commercialization
To authenticate fingerprints through glass panels poses many technical challenges and requires the redesign of circuits and the software algorithm. Goodix has been driving the development process from R&D to commercialization. Since IFS™ was launched in 2014, the company has worked closely with glass panel manufacturers and fingerprint module suppliers to ensure that the functionality, performance, reliability and supply of IFS can meet the various demands of mobile device manufacturers.
The successful commercialization of IFS™ reinforces Goodix as a global leader in biometric technology. This leading position is well recognized by global mobile brands. As of January 2017, Goodix has applied for and received more than 900 patents. The strong R&D capability propels Goodix forward to continue to innovate for mobile users. IFS™ won a Consumer Electronics Show (CES) Innovation Award in 2016, and Goodix was the first Chinese integrated circuit (IC) company to ever win this honor.
About Goodix:
Goodix , a premier developer and provider of fingerprint and touchscreen solutions for mobile phones, tablets and wearables, currently holds a diversified portfolio of fingerprint authentication solutions that provides excellent flexibility to suit the varying preferences from consumers and partners such as Live Finger Detection™, Invisible Fingerprint Sensor (IFS™), Glass-covered and Coating button sensors. In addition, Goodix has been actively involved in assisting Alipay and China UnionPay with reviewing industry standards for fingerprint authentication. An increasing number of top-tier handset manufacturers adopting fingerprints and touch solutions from the company. On October 17, 2016, Goodix was listed on the Shanghai Stock Exchange, the stock code is 603160.
Goodix™ and Invisible Fingerprint Sensor (IFS™) are trademarks of Goodix in China and other countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227006232/en/
Contact:
FleishmanHillard, on behalf of Goodix
Alisa Davis, 415-318-4086
Alisa.davis@fleishman.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom